相关临床试验
136
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1905
进行中（未招募）
6
4.4%
已完成
85
62.5%
尚未招募
10
7.3%
招募中
18
13.2%
终止
2
1.5%
Unknown
13
9.6%
撤回
2
1.5%
暂无批准数据
- Korea University's Vaccine Innovation Center and Moderna have developed an mRNA-based hantavirus vaccine that demonstrated protective efficacy in mouse studies, but human clinical trials remain stalled for over a year due to funding constraints. - The project requires 10-20 billion won for GMP facility production to advance to clinical trials, far exceeding the team's available budget despite initial support from Hyundai's 10 billion won donation. - Hantavirus affects 300-500 people annually in Korea and is classified by WHO as a potential "Disease X" pandemic pathogen, highlighting the urgent need for improved vaccines beyond the limited Hantavax currently available. - Government infectious disease R&D investment has declined significantly from 661 billion won post-COVID to 434.3 billion won in 2024, creating barriers for neglected disease vaccine development.
- Korea University researchers have demonstrated that redesigning the molecular structure of NK1 receptor antagonists can restore antidepressant effects in preclinical models after decades of failed clinical trials. - Using machine learning-based virtual screening, the team identified structurally distinct NK1R antagonists that lack the 3,5-bis-trifluoromethylphenyl group found in earlier failed drug candidates. - Lead compound #15 reduced depressive-like behaviors and neuroinflammation in mouse models of stress- and inflammation-induced depression without affecting locomotor activity. - The findings suggest that previous clinical failures may have resulted from chemical design limitations rather than flaws in the NK1 receptor target itself.
- Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021. - Korea University will conduct the first large-scale plasma proteomics study of its kind, analyzing 20,000 samples from cancer patients and healthy controls to develop AI-driven diagnostics for early-onset cancers in young adults. - The three-year study, funded by Korea's K-Health MIRAE initiative, aims to identify novel blood-based biomarkers for cancer detection in patients in their 20s and 30s using samples from leading Korean cancer institutions. - The new workflow identifies up to 10 times more proteins than conventional mass spectrometry methods and completes 80-sample batches in under 5 hours of automated runtime.
